The U.S. Food and Drug Administration has approved Impel NeuroPharma’s Trudhesa to treat migraine headaches, the Seattle company announced Friday. Trudhesa leverages Impel’s upper nasal spray system to deliver a… Read More
The greater Seattle area is a hotbed for health technology and the past year has seen groundbreaking advancements in the sector. So it’s little wonder that there’s stiff competition for… Read More
Seattle-based biotech company Impel NeuroPharma is set to go public. The company, which develops drugs for central nervous system disorders such as migraines and Parkinson’s, submitted paperwork on Friday for… Read More
F5 Networks announced in July that its longtime chief operations officer Edward Julian Eames is retiring at the end of the fiscal year. Tuesday, we learned about one of the… Read More
Seattle-based Appuri, a startup using big data in an attempt to predict customer dissatisfaction, has appointed a new CEO: former Talentwise CEO Todd Owens. Owens replaces Appuri co-founder Damon Danieli, who… Read More
Impel NeuroPharma, a Seattle-based biotechnology and pharmaceutical company, announced a $36 million Series C round to develop neurological drugs and an accompanying delivery device that bypasses the blood-brain barrier. The… Read More